Fate Therapeutics, Inc. (FATE)
Key Executives
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. J. Scott Wolchko | Founder, CEO, President & Director | 645k | 3.85M | 1970 |
Mr. Edward J. Dulac III | Chief Financial Officer | 455k | -- | 1976 |
Ms. Cindy R. Tahl J.D. | General Counsel, Corporate Secretary & Compliance Officer | 455k | 3.89M | 1973 |
Dr. Bahram Valamehr Ph.D. | Chief Research & Development Officer | 455k | 1.39M | 1977 |
Mr. Jim Beitel M.B.A. | Senior Vice President of Corporate Development | -- | -- | -- |
Dr. Jerome Bressi Ph.D. | Senior Vice President of Regulatory & Quality | -- | -- | -- |
Dr. Barbara Hickingbottom | Senior VP of Clinical Development | -- | -- | -- |
Fate Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 181
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Corporate Governance
Recent Events
- Apr 18, 2024S-3: Offering RegistrationsSee Full Filing
- Apr 16, 2024PRE 14A: Proxy StatementsSee Full Filing
- Mar 21, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Feb 26, 202410-K: Periodic Financial ReportsSee Full Filing
- Jan 24, 2024SC 13G/A: Tender Offer/Acquisition ReportsSee Full Filing